Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Status:	Completed
Conditions:	Gastrointestinal, Crohns Disease
Therapuetic Areas:	Gastroenterology
Healthy:	No
Age Range:	18 - Any
Updated:	4/21/2016
Start Date:	December 2011
End Date:	December 2014

A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease

The purpose of this study is to determine whether BMS-936557 is effective for the treatment
of moderate to severely active Crohn's Disease in patients who have had insufficient
response and/or intolerance to conventional therapy for Crohn's Disease.

Anti-IP10: Anti Interferon-inducible ligand 10

Inclusion Criteria:

- Adults subjects with confirmed Crohn's Disease (CD) for at least 3 months

- Moderate to severely active CD as defined by Crohn's Disease Activity Index (CDAI)
220 to 450

- In the past have had insufficient response and or intolerance to ≥ 1 of the
conventional therapy (immunosuppressants, corticosteroids and/or approved biologic
therapy)

Exclusion Criteria:

- Ulcerative colitis (UC) or indeterminate colitis

- Short bowel syndrome

- Known stricture or noninflammatory stenosis leading to symptoms of obstruction

- Current stoma or current need for colostomy or ileostomy

We found this trial at

sites

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina 27599

(919) 962-2211